NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
08/18/2026
Back to search
Official data from USPTO
ROSCH IMMUNOTHERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ROSCH IMMUNOTHERAPY
ST13
US500000086778557Class
9
Filing
86778557
Registration
4982716
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
08/18/2026
Trademark type
Word
Nice classes
9
Filing date
10/05/2015
Registration date
06/21/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/18/2026
Last transaction
08/18/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
12/01/2004
First use in commerce
12/01/2004
Drawing code
4
Owner type
03
Owner location
Altoona, PA, US
Examiner
VERHOSEK, WILLIAM T
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Rosch Visionary Systems, Inc.
Representatives
Christopher T. Michelone MCQUAIDE BLASKO, INC.
Technical classification
Nice Classes
Class 9
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Computer application software for personal computerssoftware for allergy practices and patients to assist and supplement patient care
Publications
History of USPTO decisions and trademark events.
25 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
08/18/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
08/18/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/18/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
06/22/2026
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/21/2025
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
11/20/2021
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
11/20/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/20/2021
E815
TEAS SECTION 8 & 15 RECEIVED
08/18/2021
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/21/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
06/21/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/05/2016
PUBO
PUBLISHED FOR OPPOSITION
04/05/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/16/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/01/2016
ALIE
ASSIGNED TO LIE
02/25/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/26/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
01/26/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/26/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
01/26/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/26/2016
DOCK
ASSIGNED TO EXAMINER
01/25/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/08/2015
NWAP
NEW APPLICATION ENTERED
10/08/2015
Continuous trademark protection
Get notified about every new filing that threatens ROSCH IMMUNOTHERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.